arcoris bio Raises CHF 6.3 Million Seed Round to Advance Next-Generation Biomarker Detection Platform
arcoris bio, the Swiss life sciences startup developing next-generation biomarker detection solutions for research and diagnostics, has secured a significant CHF 6.3 million (~€6.7 million) seed financing round to advance its flagship MUSE® platform in digital pathology and spatial multi-omics. Founded in 2022 by inventors Simon Restrepo and Scott E. Fraser alongside entrepreneur H. Kaspar Binz, the company is headquartered in Schlieren, Switzerland, and is focused on enabling highly sensitive, universal biomarker detection that could transform how researchers and clinicians interpret complex biological data.
The seed round, announced in November 2025, was co-led by institutional backers Ventura Ace and ZEISS Ventures, with additional participation from Zürcher Kantonalbank (ZKB) and a mix of new and existing private investors. This diverse investor base validated arcoris bio’s technical direction and reinforced confidence in its potential to industrialize and scale its innovative MUSE biomarker detection technology.
The funding will be used to accelerate the commercialization of the MUSE platform, expand the company’s strategic partnerships, and support the launch of new products to broaden its applications in digital pathology, drug discovery, and precision medicine. MUSE’s nanotechnology-driven approach enables simultaneous detection of multiple biomarkers within a single sample with high sensitivity and throughput, potentially offering researchers and clinicians deeper insights into tissue microenvironments and cellular dynamics.
arcoris bio’s leadership emphasized the importance of securing this capital in a challenging market. Company CEO Matyas Vegh said the financing marked a major milestone, enabling the firm to bring its innovations to market more rapidly, strengthen operations, and scale to meet growing industry demand. The funding also strengthens the company’s ability to compete in a rapidly evolving diagnostics tools landscape where demand for robust, multiplexed biomarker solutions is rising globally.
The co-lead investor Ventura Ace is an early-stage life sciences investor with a focus on transformative biomedical technologies. Its participation underscores interest in supporting startups that tackle critical gaps in diagnostics and research workflows. Meanwhile, ZEISS Ventures, the corporate venture capital arm of the ZEISS Group, brings not only capital but strategic industry expertise and access to a broad network within the optics, imaging, and microscopy sectors. Zürcher Kantonalbank, one of Switzerland’s major financial institutions, joined the round, contributing regional financial strength and reinforcing local support for the startup’s growth.
The MUSE platform itself is positioned as a next-generation tool that overcomes limitations of current biomarker detection systems, providing what company spokespeople describe as programmable, universal signal amplification. This capability allows researchers to obtain more comprehensive, data-rich assay results, which is crucial for applications ranging from cancer research to immunology and translational medicine. Such technological breakthroughs are increasingly sought after as life science research shifts toward more complex, multi-dimensional data interpretation.
arcoris bio’s strategy reflects broader trends in the life sciences and diagnostics fields, where startups that can bridge high-precision hardware and software with scalable workflows are attracting early funding even at initial stages. The oversubscribed nature of the seed round indicates strong investor belief in both the MUSE technology and the company’s leadership team.
The infusion of capital comes at a time when the global diagnostic tools market continues to expand, driven by an increasing need for personalized medicine, high-throughput screening, and advanced imaging solutions. By focusing on spatial multi-omics and digital pathology, arcoris bio aims to position itself at the forefront of this growth, offering solutions that enhance existing biomarker platforms and support clinicians and researchers in deriving actionable insights from complex biological systems.
Looking ahead, arcoris bio plans to use the seed funding to industrialize its platform, build out its product portfolio, and deepen collaborations with research organizations and strategic commercial partners. With a strong foundation of institutional and private backing, the company is preparing to scale its operations and move closer to realizing its vision of enabling precise diagnosis and personalized treatment through next-generation biomarker technologies.
